Targeted drug shows promise for rare bone cancer
NCT ID NCT05041127
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether cetuximab, a targeted antibody drug, can shrink tumors in people with advanced or metastatic chordoma, a rare type of bone cancer. About 29 adults with inoperable or spread chordoma will receive cetuximab intravenously. The main goal is to see how many patients respond to treatment, with safety also closely monitored.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cetuximab (a targeted antibody drug given intravenously)
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced chordoma, a rare bone cancer with limited therapies.
- What could go wrong
- This is a small, early-phase trial with only 29 participants and no comparison group, so results may not be conclusive. Cetuximab can cause skin reactions and other side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHORDOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill stall advanced sarcomas?
- How do patients feel after Nose-Based brain surgery? new study aims to find out
- New drug shows promise for rare spine cancer
- New gene therapy offers hope for advanced cancers
- New proton therapy could shrink skull tumor treatment to just 5 days
- Promising drug combo targets rare spine tumor